In October 2022, The Stock Exchange of Hong Kong Limited issued a consultation paper to seek public feedback on proposals for new listing rules for Specialist Technology Companies.
Similar to the launch of the pre-revenue biotech listing regime in 2018, the Exchange aims to relax the listing requirements for innovative Specialist Technology Companies with high growth potential to list on the Exchange.
With these proposals, the Exchange aims to emulate the success it has received with the Biotech Listing Regime, which has elevated the Exchange into being Asia’s largest and the world’s second largest biotech fundraising hub. Such success contributes to the continuing competitiveness of the Exchange, and by extension, Hong Kong as one of Asia’s leading financial centres.
The Consultation concluded in December 2022, with the regime being expected to be implemented as Chapter 18C of the Rules Governing the Listing of Securities on the Exchange in Q2 2023.
Click here to read more.
